TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05042440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efanesoctocog alfa
Description: Solution for injection Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octocog alfa
Description: Solution for injection Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rurioctocog alfa pegol
Description: Solution for injection Intravenous
Study: NCT06428695

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: one-hour dietary self-monitoring tool education session
Description: access the impact of a one-hour dietary self-monitoring tool education session for participants in a calorie-restricted weight management program on their knowledge of the use of the tool to help them adhere to a calorie-restricted weight management program
Study: NCT06571942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide / Formoterol / Glycopyrronyum 160/4.8/7.2 mcg
Description: Two inhalations twice daily form pMDI device for three months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide / Formoterol / Glycopyrronyum 160/4.8/7.2 mcg
Description: Two inhalations twice daily form pMDI device for three months
Study: NCT06569862

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative day 1 dressing
Description: The patient's dressing will be removed on the first day after surgery, leaving the incision exposed to air, with daily cleaning.
Study: NCT06230627

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-Based Rehabilitation rogram
Description: The intervention is distinguished from others in that it applies to patients' homes and the trial was followed up in the middle of complex conditions of the COVID-19 Pandemic. Also, the challenge was represented by the HBRP applied to patients with SCIs after 4-5 years of rehabilitation interruption.
Study: NCT05321823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iBreast device
Description: The iBreast (iBE) device is an automated, battery powered, portable device designed to be used by community health nurses as a screening and triage tool. The iBE is designed to be used by a community health worker or lay person after appropriate training. In resource-limited settings, it potentially provides an easily accessible, low-cost method to assess the breast for findings that warrant further evaluation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Breast Examination
Description: The standard clinical breast examination (CBE) will be performed by the community health nurses in the selected primary health care centers where patients will present for screening or diagnostic workup in the intervention community

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Breast ultrasound
Description: Women in the intervention community who have positive iBE and/or CBE findings will be navigated by the community health nurses to have ultrasound with or without ultrasound-guided breast biopsy if indicated by the radiologist using portable ultrasound tablets that will be brought to the intervention community.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mammography
Description: Women in the intervention community who have positive iBE and/or CBE findings will be navigated by the community health nurses to have mammography done using a mobile mammography van that will be brought to the intervention community.
Study: NCT05532488

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin 20 mg
Description: Inulin can increase gut Bifidobacterium count. Bifidobacterium has beneficial effects on the metabolic profile and insulin resistance biomarkers.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05981287

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task-oriented activities based on NDT (TOA-NDT) principle and Conventional Physical Therapy
Description: This will be a randomized clinical trial. patients are divided into two groups. one of them will undergo task-oriented activities along with conventional physical therapy treatment, while the other will undergo gross motor task training along with conventional physical therapy treatment. Purpose is to determine that which of them has greater benefit in improving balance trunk control and functional mobility in children with cerebral palsy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gross motor task training and Conventional physical therapy (CPT)
Description: This will be a randomized clinical trial. patients are divided into two groups. one of them will undergo task-oriented activities along with conventional physical therapy treatment, while the other will undergo gross motor task training along with conventional physical therapy treatment. Purpose is to determine that which of them has greater benefit in improving balance trunk control and functional mobility in children with cerebral palsy.
Study: NCT04862884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS4800 tablets
Description: 1. Drug: HRS4800 tablets Low-dose group, single oral administration~2. Drug: HRS4800 tablets Low-medium dose group, single oral administration~3. Drug: HRS4800 tablets medium -dose group, single oral administration~4. Drug: HRS4800 tablets Medium and high dose group, single oral administration~5. Drug: HRS4800 tablets High-dose group, single oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1. Drug: placebo Low-dose group, single oral administration~2. Drug: placebo Low-medium dose group, single oral administration~3. Drug: placebo medium -dose group, single oral administration~4. Drug: placebo Medium and high dose group, single oral administration~5. Drug: placebo High-dose group, single oral administration
Study: NCT05612139

Intervention type: DEVICE
Intervention: JTIN implantation surgery
Description: The JTIN is a self-extending intramedullary nail (telescopic rod) designed to provide fixation of femoral and/or tibial fractures, osteotomies, malunions and non-unions. The design of the JTIN includes a female and a male component, which are anchored to the proximal cortex and distal epiphysis through screw-type fixation. These two components slide from each other, allowing for extension of the JTIN as the bone structures remodel and patient growth occurs.
Study: NCT06569862

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Postoperative day 6+/-1 dressing
Description: The patient will have a daily dressing change according to the usual nursing procedures, including saline serum washing, until the sixth day (+/- 1 day) after surgery. This will be done while the patient is in hospital, or at home if discharged before the sixth day.
Study: NCT05627921

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy
Description: Spastic muscles will be determined by examination. Botulinum toxin-A will be injected into the spastic muscles with Stumplex. 1 week after the injection, patients will receive 3 sessions of radial ESWT treatment, 1 session/week. rESWT application will be applied with the 'MODUS ESWT' device and a 35 mm radial soft applicator will be used. rESWT will be applied with a soft applicator. The soft applicator is designed for application to sensitive and painful areas and applications will be painless.Shock waves will be applied at 1500/beat, 8 Hz, 0.030 Mj/mm2, 2 bar per muscle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botilinum Toxin injection
Description: Spastic muscles will be determined by examination. Botulinum toxin-A will be injected into the spastic muscles with Stumplex.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botilinum Toxin injection
Description: Spastic muscles will be determined by examination. Botulinum toxin-A will be injected into the spastic muscles with Stumplex.
Study: NCT06416202

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Advanced hybrid closed loop insulin pump
Description: All groups will receive comprehensive diabetes education and extensive carbohydrate counting training. Continuous glucose monitoring (CGM) will be conducted using the Guardian 4 sensor or Dexcom G6 for the intervention group depending on the type of pump used. fructosamine levels for all patients will be checked both before and after Ramadan to provide a more immediate assessment of glycemic control.

Intervention type: OTHER
Group type: OTHER
Intervention: Open Loop Insulin Delivery system
Description: the control group will continue using their current CGM device. Data on glycemic control, hypoglycemic events, and patient satisfaction will be collected before and throughout Ramadan. Additionally, fructosamine levels for all patients will be checked both before and after Ramadan to provide a more immediate assessment of glycemic control.
Study: NCT06548217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538HSC
Description: ONO-4538HSC will be administered subcutaneously once every 4 weeks.
Study: NCT05482295

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine lot 1
Description: 3 doses of Hepatitis B vaccine lot 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine lot 2
Description: 3 doses of Hepatitis B vaccine lot 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine lot 3
Description: 3 doses of Hepatitis B vaccine lot 3

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B vaccine (registered)
Description: 3 doses of Hepatitis B vaccine (registered)
Study: NCT06248359

Intervention type: DRUG
Intervention: L-Arginine hydrochloride
Description: Postoperative administration of L-Arginine hydrochloride before incidence of CS-AKI
Study: NCT06345612

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hypoxia
Description: eccentric training program conducted within normobaric hypoxic chamber

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hypoxia
Description: eccentric training program conducted within normobaric hypoxic chamber

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: normoxia
Description: eccentric training program conducted within normoxic conditions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: normoxia
Description: eccentric training program conducted within normoxic conditions

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: creatine supplementation
Description: 5g of creatine per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: creatine supplementation
Description: 5g of creatine per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: no creatine supplementation
Description: no creatine supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: no creatine supplementation
Description: no creatine supplementation
Study: NCT04860258

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVnCoV Vaccine
Description: Intramuscular (IM) injection in the deltoid area, preferably in the non-dominant arm.
Study: NCT05285514

Intervention type: DIAGNOSTIC_TEST
Intervention: Comparison of macro- and microcirculatory parameters
Description: Microcirculation examination using sublingual videomicroscopy, tissue O2 saturation (StO2) by NIRS and transcutaneous CO2 pressure (tcpCO2) monitoring, in conjunction with macrocirculatory parameters measures including cardiac output, arterial pressure and pulsed O2 saturation, in order to establish the relationship between the macrocirculatory changes in blood pressure and cardiac output and the microcirculatory flow and capillary density during vasoactive agent use. . Participants receive interventions as part of routine medical care to restore Cerebral Perfusion pressure (CPP) to appropriate levels (60-70 mmHg)
Study: NCT06421090

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transauricular Vagal Nerve Stimulation
Description: Transauricular vagal nerve stimulation，Intervention group25Hz，Control group1Hz

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transauricular Vagal Nerve Stimulation
Description: Transauricular vagal nerve stimulation，Intervention group25Hz，Control group1Hz
Study: NCT05831670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSP-0243
Description: Oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration
Study: NCT04604236

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mapping Enhanced Counseling
Description: Practitioner-led, collaborative discussion with the youth and their caregiver on co-creating guide maps for decision making around starting treatment and continuing substance use that can help users organize information and think through a series of steps, questions, and behavior choices. encountered when attempting to initiate substance use treatment services. MEC is a communication and decision-making approach that uses graphic visualization tools to train individuals to monitor and control their decision making, improve judgment and behavioral choices (self-regulation), and improve communication and mutual understanding.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Linkage
Description: Practitioner-led, collaborative discussion with the youth and their caregiver on how to overcome barriers encountered when attempting to initiate substance use treatment services. Discussion focuses around the top barriers identified through assessment and identification of 1 or more treatment agency/options that fit the family's needs. Practitioner takes a more active role in addressing barriers to treatment by helping the family find ways to access resources for payment, childcare, or other needs, and actively linking them to the treatment provider (e.g., scheduling the initial appointment with family present).
Study: NCT05308225

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STI-6129
Description: Anti-CD38 A2 human antibody drug conjugate (ADC) containing an antibody covalently bound to a duostatin tubulin inhibitor
Study: NCT05458141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FYA-003
Description: FYA-003: It is a gamified health education module for children aimed at promoting healthy nutrition, physical activity, health hygiene, and infectious diseases risk reduction within the clinically proven app fooya!
Study: NCT06106087

Intervention type: OTHER
Group type: OTHER
Intervention: Mixed methods quality improvement intervention
Description: Quality improvement training for frontline PCH staff
Study: NCT05721612

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flapless transcrestal sinus lift approach with TPRF
Description: Including 8 patients who will be treated by flapless transcrestal sinus floor elevation using the TPRF as a sole grafting material.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flapless transcrestal sinus lift approach with PRF
Description: Including 8 patients who will be treated by flapless transcrestal sinus floor elevation using the PRF as a sole grafting material.
Study: NCT05315336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-DEP and PD-1 antibody
Description: Doxorubicin (doxorubicin hydrochloride liposome injection) 25 mg/m2 day 1; etoposide 100 mg/m2 was administered day1; methylprednisolone 2mg/kg days 1 to 3,then 0.25mg/kg day 4 to 14; PD-1 antibody injection 200mg day 5; L-asparaginases 6000iu/m2 day2, day4. This regimen was repeated after 2 weeks.
Study: NCT05537766

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brexucabtagene Autoleucel
Description: Administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brexucabtagene Autoleucel
Description: Administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brexucabtagene Autoleucel
Description: Administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brexucabtagene Autoleucel
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously
Study: NCT05380505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Racially Congruent Ads
Description: Facebook food ads that are racially congruent.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Racially Incongruent Ads
Description: Facebook food ads that are racially incongruent.
Study: NCT05949125

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (Non-IMP, Lymphodepletion)
Description: Intravenous infusion over 3 days (d-5 to d-3)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludarabine (Non-IMP, Lymphodepletion)
Description: Intravenous infusion over 3 days (d-5 to d-3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-TM123
Description: Intravenous infusion over 20 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allo-RevCAR01-T
Description: A single dose of Allo-RevCAR01-T will be administered as IV infusion on Treatment day 1. Allo-RevCAR01-T will not be administered again within this study.
Study: NCT06354738

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total hysterectomy with bilateral salpingo-oophorectomy, lymph node staging and comprehensive peritoneal staging
Description: Surgical treatment will consist of total hysterectomy with bilateral salpingo-oophorectomy according to international guidelines.~In low- and intermediate-risk EC patients, staging will include a sentinel lymph node (SLN) procedure. In high intermediate-risk and high-risk EC patients, lymph node staging will involve SLN procedure and/or pelvic and para-aortic lymph node dissection (LND), depending on the local protocol.~The Study-related procedures include infracolic omentectomy or two separate omental representative biopsies, biopsies of all suspicious lesions as well as six peritoneal sites (bladder, pouch of Douglas, bilateral paracolic gutter and bilateral diaphragm).~Stage IV patients will be treated according to European guidelines. When feasible, full surgical intervention (i.e. debulking) is recommended. If this cannot be achieved, a radiologic and/or histologic confirmation of tumor spread beyond the uterus will be accepted.
Study: NCT05622188

Intervention type: OTHER
Intervention: Elevated ambient heat
Description: Temporary exposure to increased ambient temperature +10°C (the effect of the intervention is fully and spontaneously reversible)

Intervention type: OTHER
Intervention: Elevated relative humidity
Description: Temporary exposure to increased ambient relative humidity +40% (max. 90%) (the effect of the intervention is fully and spontaneously reversible)

Intervention type: OTHER
Intervention: Exertion
Description: Temporary exertion on an ergometer (1W/kg body weight) (the effect of the intervention is fully and spontaneously reversible)
Study: NCT06000618

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrapulmonary Percussive ventilator
Description: The volunteers will undergo three minutes low frequency and high frequency intrapulmonary percussive treatments.
Study: NCT06064786

Intervention type: DIAGNOSTIC_TEST
Intervention: GCF levels of fetuin A and hsCRP evaluation
Description: ELIZA kits are used for GCF levels of fetuin A and hsCRP evaluation

Intervention type: DIAGNOSTIC_TEST
Intervention: GCF levels of fetuin A and hsCRP evaluation
Description: ELIZA kits are used for GCF levels of fetuin A and hsCRP evaluation

Intervention type: DIAGNOSTIC_TEST
Intervention: GCF levels of fetuin A and hsCRP evaluation
Description: ELIZA kits are used for GCF levels of fetuin A and hsCRP evaluation
Study: NCT04726813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyADHD
Description: The main goals of the intervention are to help participants with better functioning in daily life; offer strategies that will lead to stress reduction and reduce inattention and improve quality of life.The intervention includes: a short introductory chapter (open to everyone), followed by a start module (goal setting), followed by 6 different themed optional modules. Module content is based on GMT, DBT and CBT techniques and is tailored towards key concerns and difficulties experienced adults with ADHD as informed by previous research (focus-groups, lived experience groups) and experiences from group GMT and DBT.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducation
Description: Participants in the control condition will be assigned to psychoeducation modules (see Table 2) and will receive restricted access to the platform. They can contact or be contacted if their symptoms levels increases.
Study: NCT05154942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DOXO+electroacupuncture
Description: DOXO+electroacupuncture
Study: NCT04983745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination drug
Description: niraparib and dostarlimab combination
Study: NCT05079061

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: sublingual misoprostol 600 micrograms in addition routine uterotonics at third stage of labour
Study: NCT05435586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web Based Breastfeeding Education and Counseling with Digital Game Support
Description: The educational content prepared by the researcher on the web page will be integrated into the game program designed with the gamification technique. In this designed program, users will be notified at appropriate times to enter the system and play games from the link sent via e-mail. After the users have finished the game, they will fill the scale in the relevant week and will only be able to exit the system in that way.
Study: NCT05196243

Intervention type: OTHER
Intervention: Patients diagnosed as gastrointestinal mucosal lesions
Description: Patients diagnosed as gastritis, gastric cancer, intestinal polyps and colorectal cancer